Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-rhG-CSF for neutrophil recovery in lymphoma and multiple myeloma
NCT06060080Unknown
- Start
- Apr 2022
- Primary completion
- Dec 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of pegfilgrastim in lymphoma and multiple myeloma (MM). Primary endpoint: Median time to neutrophil cell reconstruction at 21 days. Status: unknown.
02
Drugs
pegfilgrastim
03
Conditions
lymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT06060080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06060080.